<DOC>
	<DOCNO>NCT01747629</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy Albuterol Spiromax® versus placebo subject persistent asthma .</brief_summary>
	<brief_title>Efficacy Inhaled Albuterol Spiromax® Subjects With Persistent Asthma With Steady State Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Written inform consent/assent At least 12 year age screen General good health Persistent asthma ≥3 month , FEV1 5080 % predict ≥15 % reversibility Taking inhaled corticosteroid stable dose ( ≤ equivalent 500mcg fluticasone propionate/day ) least 4 week prior Screening Visit . Ability perform spirometry acceptable manner per protocol guideline Other inclusion criterion apply A known hypersensitivity albuterol excipients formulation . History respiratory infection disorder resolve within 1 week precede Screening Visit ( SV ) . History lifethreatening asthma define protocol asthma episode require intubation . Any asthma exacerbation require oral corticosteroid within 3 month SV . A subject must hospitalization asthma within 6 month prior SV . Hospitalization due asthma exacerbation 2 time past year Initiation immunotherapy dose escalation study period Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>dry powder inhaler</keyword>
	<keyword>short-acting beta2-agonist</keyword>
	<keyword>SABA</keyword>
	<keyword>bronchoconstriction</keyword>
	<keyword>bronchodilation</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>meter dose inhaler</keyword>
	<keyword>Albuterol Spiromax®</keyword>
</DOC>